The decrease in paclitaxel CL noticed from the presence of zosuquidar led to a boost in time that the plasma paclitaxel focus stays over 0.one mol L−one, which is known to be a marker of each toxicity (neutropenia) and efficacy [1]. Although the result of zosuquidar within the toxicity of https://alfredt998epz1.aboutyoublog.com/profile